DGAP-News: MagForce AG / Key word(s): Miscellaneous
MagForce AG: MagForce AG Announces that Kiel University Hospital
(UKSH) has Initiated Commercial NanoTherm(TM) Treatment for Brain
Cancer
27.03.2015 / 08:45
---------------------------------------------------------------------
MagForce AG Announces that Kiel University Hospital (UKSH) has Initiated
Commercial NanoTherm(TM) Treatment for Brain Cancer
Berlin, Germany and Nevada, USA, March 27, 2015 - MagForce AG (Frankfurt,
Entry Standard, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device
company in the field of nanomedicine focused on oncology, today announced
that the Department of Neurosurgery at Kiel University Hospital (UKSH),
headed by Professor Dr. Hubertus Maximilian Mehdorn, has initiated
NanoTherm(TM) therapy in the commercial setting for the treatment of brain
cancers.
After the start of commercial treatments of brain cancers at the University
Hospital in Munster in February, this marks another milestone for MagForce
with now two world class medical centers offering NanoTherm(TM) therapy
also in the commercial setting.
"Since we announced the first commercial patient in February this year
based on our European approval for the treatment of brain cancer, we have
observed a significantly increased interest of patients, national as well
as international, for the treatment with our innovative NanoTherm(TM)
therapy in Germany. We are especially pleased with the successful
interaction with the key opinion leaders in the medical community.
Preparations for the approval process in the US both for brain cancer and
prostate cancer are well on track, hence, 2015 is set to be a
transformational year for MagForce, marking first commercial revenues and
global expansion," commented Dr. Ben J. Lipps, CEO of MagForce AG and
MagForce USA, Inc.
About MagForce AG and MagForce USA, Inc.
MagForce AG, listed in the entry standard of the Frankfurt Stock Exchange
(MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc.
is a leading medical device company in the field of nanomedicine focused on
oncology. The Group's proprietary NanoTherm(TM) therapy enables the
targeted treatment of solid tumors through the intratumoral generation of
heat via activation of superparamagnetic nanoparticles. Mithril Capital
Management, a growth-stage technology fund founded by Ajay Royan and Peter
Thiel, along with MagForce AG, are investors and strategic partners in
MagForce USA, Inc.
NanoTherm(TM), NanoPlan(R), and NanoActivator(R) are components of the
therapy and have received EU-wide regulatory approval as medical devices
for the treatment of brain tumors. MagForce, NanoTherm(TM), NanoPlan(R),
and NanoActivator(R) are trademarks of MagForce AG in selected countries.
For more information, please visit: www.magforce.com
Disclaimer
This release may contain forward-looking statements and information which
may be identified by formulations using terms such as "expects", "aims",
"anticipates", "intends", "plans", "believes", "seeks", "estimates" or
"will". Such forward-looking statements are based on our current
expectations and certain assumptions, which may be subject to a variety of
risks and uncertainties. The results actually achieved by MagForce AG may
substantially differ from these forward-looking statements. MagForce AG
assumes no obligation to update these forward-looking statements or to
correct them in case of developments, which differ from those, anticipated.
Contact:
Anne Hennecke
MC Services AG
T +49 211 529252-22
F +49 211 529252-29
Email: anne.hennecke@mc-services.eu
---------------------------------------------------------------------
27.03.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: MagForce AG
Max-Planck-StraÃe 3
12489 Berlin
Germany
Phone: +49 (0)30 308 380 0
Fax: +49 (0)30 308 380 99
E-mail: info@magforce.com
Internet: www.magforce.com
ISIN: DE000A0HGQF5
WKN: A0HGQF
Listed: Regulated Unofficial Market in Berlin, Dusseldorf,
Stuttgart; Open Market (Entry Standard) in Frankfurt
End of News DGAP News-Service
---------------------------------------------------------------------
338393 27.03.2015
DGAP-News: MagForce AG: MagForce AG Announces that Kiel University Hospital (UKSH) has Initiated Commercial NanoTherm(TM) Treatment for Brain Cancer
| Source: EQS Group AG